Member Info for BuenaVista

Do you have any issue with the substance of what I wrote? If so, I'd like to hear it

"Worst case? It replaces straight dox (same efficacy) with fewer side effects. That takes the entire marker ($1Bn plus as a chunky CAGR)."

It is wrong to equate the doxorubicin market with the future AVA6000 market as doxorubicin is given for cancers where FAP is not upregulated. There are other differences (both positive and negative wrt AVA6000) between the two markets but that one is fundamental.

And hopefully more wonderful weeks to come with further announcements in the lead-up to Science Day.

You know that our 'precision' tech has a trademarked name? pre|CISION, or pre|CISION™ to be exact.

Good point. Nice find.

Also, note the size of the women-specific ovarian and breast cancer markets.

To quote from that document:

Intravenous Chemotherapy Regimens Suitable for Scalp Cooling
Scalp cooling can be used with all solid tumour cancers treated with intravenous SACT
agents such as taxanes, alkylating agents and anthracyclines / DNA intercalating agents. The
most suitable agents include:
• Cyclophosphamide
• Daunorubicin
• Docetaxel
• Doxorubicin
• Epirubicin
• Paclitaxel

Three of these, the -rubicins, are anthracyclines.
QUESTION: Would AVA6000 replace other anthracyclines? Do the others have a big advantage in certain treatment regimens?

Regarding the OP's comment and Avacta's "This is extremely encouraging as we work towards realising our vision of "chemotherapy without side effects" to make a meaningful difference to cancer patients' lives.", although WORKING TOWARDS it, this VISION has obviously not been acheived yet as AVA6000 is not being given as a therapy to PATIENTS.

It is a statement of where Avacta want to be, and Tuesday's announcement was a significant step along the path there.

Are you talking about precision medicine or pre|CISION?

Topped up early this morning with a near double of my existing holding when my limit order to buy was triggered at 2.5% below my set price. Very happy. Could trade as that large buy is now well in profit but I'm a LTH so won't.

As regards fair value, have a listen here:
https://www.youtube.com/watch?v=2l1ZSR2KOP4&t=2220s

I see he's got you all talking about him.

Will you lot ever learn? So f'in immature. Grow up ffs.

I don't remember this being posted at the time, nor since. Gervais Williams, manager of Premier Miton's Diverse Income Trust, and long-term holder of Avacta interviewed by the ever-talkative Paul Hill.

https://www.youtube.com/watch?v=2l1ZSR2KOP4
(30 November 2022)

Avacta is at 06:05 (short-cut in the description). Worth listening to a few of the other small companies talked about... why does he fall over his words so much when talking positively about Avacta's future?...

See, that we call him Alan

Re your 1)
If that were the case (e.g. 50% of standard doxorubicin at the tumour site), then the answer will be in the PK data. Essentially, how much and how long are AVA6000, 5140 and doxorubicin and its metabolites circulating before being excreted? I.e. if there isn't much doxurubicin in the tumour and we're not seeing the usual doxorubicin side effects, then what the hell has happened to all the infused AVA6000?

A solution to this would not necessarily be to increase the therapeutic dose in the clinic, but might be to give a slower infusion and/or more frequent infusions - both methods giving FAP more time to cleave the passing AVA6000.

Please sell SZ so that the SP can rise again.

Whether or not they have photos and life story of a patient successfully treated, I think the 'IMPROVED chemo WITHOUT side-effects' story would easily go global now.

Coffee and bagels, and egg over easy on waffle breakfast served up now at SkyCafe.

They're getting ready.

158-62 pre NY, 100/ size buyer back, 150/ "working order" coming, BEGO on the bid as ever.

Not long now.

SP dip coming. Usual.

Doc Holliday talks to Alan Green! Good find. Thanks.

People, people, please, please, please just ignore Derek and Dacia.

There is ABSOLUTELY no point in TRYING to engage in discussion with them. They are not interested in the slightest in your arguments except to find an angle to come back at. It is a stupid, never-ending lot of drivel.

And they just love your 'insults' - it just means they've got under your skin.

Just stop it. Please. Be mature.

Avacta's Therapeutics division needs to ensure that all these are complied with:

Good Laboratory Practice (GLP)
https://en.wikipedia.org/wiki/Good_laboratory_practice

Good Clinical Practice (GCP)
https://en.wikipedia.org/wiki/Good_clinical_practice

Good Manufacturing Practice (GMP)
https://en.wikipedia.org/wiki/Good_manufacturing_practice

Too early. Details in RNS and probably (non-peer-reviewed) conference abstract(s) first.

If this is comprehensive (Last Updated: October 24, 2022), Novartis will still have so much cash they can afford banknote toilet paper in their gold rest rooms.

https://tracxn.com/d/acquisitions/acquisitionsbyNovartis